Physician profile
Michael J Morse
NPI 1346245230
$2,752.99
in general payments reported to CMS, 2019-2025
28 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $164 · 2021: $13.46 · 2022: $237 · 2023: $632 · 2024: $552 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453 · Travel and Lodging: $21.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.93 |
| Travel and Lodging | $21.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $454.83 | 2019-2025 | Grafix Pl, Stravix Pl, Renasys Go V2 Home |
| Kerecis Limited | $347.76 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Bioventus LLC | $269.40 | 2019-2022 | |
| Convatec INC. | $169.55 | 2023-2024 | |
| Amgen INC. | $159.67 | 2025 | Krystexxa |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.55 | 2019-2023 | Jublia |
| Melinta Therapeutics, LLC | $136.08 | 2019 | |
| Paratek Pharmaceuticals, INC. | $119.31 | 2024 | Nuzyra |
| Triad Life Sciences INC. | $112.04 | 2022 | |
| Biopro, INC. | $105.49 | 2020 | |
| Ironshore Pharmaceuticals INC. | $87.93 | 2024 | |
| Merck Sharp & Dohme LLC | $82.92 | 2019 | |
| Averitas Pharma INC. | $78.21 | 2023-2025 | Qutenza |
| Musculoskeletal Transplant Foundation INC. | $78.11 | 2019 | |
| Nevro Corp. | $63.72 | 2023 | Senza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $50.79 | 2020-2023 | Krystexxa |
| Fidia Pharma USA INC. | $41.39 | 2019 | |
| Osiris Therapeutics INC. | $38.49 | 2019 | |
| Stryker Corporation | $35.71 | 2023 | Viaflow, Prophecy |
| Sandoz INC. | $27.40 | 2019 | |
| Solventum Corporation | $24.83 | 2025 | Activ.A.C. |
| Next Science LLC | $23.45 | 2023 | Surgx, Xperience, Blastx |
| Mimedx Group, INC. | $21.33 | 2024 | |
| Sebela Pharmaceuticals INC. | $18.87 | 2023 | Pramosone, Naftin |
| Organogenesis INC. | $16.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.10 | 2023 | Seglentis |
| Hikma Pharmaceuticals USA | $13.46 | 2021 | |
| Arthrosurface Incorporated | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.